Pirfenidone (Esbriet) capsules 267mg: Discontinuation
Roche is discontinuing pirfenidone capsules 267mg. They are being replaced by pirfenidone film-coated tablets 267mg.
Why is this happening?
Due to decreasing demand, Roche has decided to discontinue the pirfenidone capsules globally. This action was to ensure continuity of supply for the tablets. This discontinuation is not related to any safety concerns.
Pirfenidone film-coated tablets listed 1 August 2021
- 1 August 2021: Pirfenidone tablets 267mg (2602156) pack size 90 listed
- November 2021: Pirfenidone capsules 267mg (2505932) pack size 270 stock is expected to be exhausted
Roche expects the capsules to run out in November 2021.
The capsules will be delisted on 1 January 2022.
We know change can be inconvenient. We appreciate the work our pharmacists and health care professionals do to support people when we have to change a medicine.
Capsules and tablets interchangeable
The capsules and tablets have been shown to be bioequivalent. This means that they contain the same active ingredient, in the same amount, and delivered to the body in the same way.
The only notable difference between the products is the pack size.
The tablets are Medsafe-approved. Information about excipients (non-active ingredients) is available on Medsafe's website.
You can read Roche's letter to the Thoracic Society of Australia and New Zealand (TSANZ) and the Asthma and Respiratory Foundation NZ.
Who to contact
Healthcare professionals can contact Roche to discuss this discontinuation.
If you take pirfenidone, talk to your pharmacist, doctor, or the person who prescribed this medicine. They know you and your needs best. Pharmac cannot give individual clinical advice.